Results 81 to 90 of about 5,418,578 (179)

Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma

open access: yesJournal of Cellular Physiology, Volume 241, Issue 5, May 2026.
ABSTRACT Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for
Pegah Rahimizadeh   +4 more
wiley   +1 more source

MRI features of an intra‐articular histiocytic sarcoma affecting the stifle joint in a dog

open access: yesVeterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract A 13‐year‐old, spayed, female German shorthaired pointer was presented for investigation of a right pelvic limb lameness and associated marked stifle swelling. Magnetic resonance imaging revealed a mildly heterogeneous, T2‐weighted hyperintense and T1‐weighted homogeneously hypointense, contrast‐enhancing fine nodular mass arising from the ...
Harriet Rhodes   +2 more
wiley   +1 more source

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development

open access: yesDrug Design, Development and Therapy, 2020
Brooke Benner,1,* Logan Good,1,* Dionisia Quiroga,2 Thomas E Schultz,3 Mahmoud Kassem,2 William E Carson,1 Mathew A Cherian,2 Sagar Sardesai,2 Robert Wesolowski2 1Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Benner B   +8 more
doaj  

Case report: Tenosynovial giant cell tumor

open access: yesFrontiers in Oncology
Tenosynovial giant cell tumor (TGCT) is a rare type of tumor that originates from the synovium of joints and tendon sheaths. It is characterized by recurring genetic abnormalities, often involving the CSF1 gene. Common symptoms include pain and swelling, which are not specific to TGCT, so MRI and a pathological biopsy are needed for an accurate ...
Anke Fähnrich   +24 more
openaire   +3 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Localized Giant Cell Tenosynovial Tumor Seen in the Knee Joint

open access: yes, 2014
Tenosynovial giant cell tumor is a locally aggressive tumor arising from the synovia of the fibrous tissue surrounding the joints, tendon sheaths, mucosal bursas, and tendons.
Cem Albay   +6 more
core   +1 more source

Management of germ cell tumors in children: Approaches to cure [PDF]

open access: yes, 2002
The introduction of cisplatinum chemotherapy and current advances in the surgical treatment have resulted in a dramatic improvement of the prognosis of children with malignant germ cell tumors (GCT).
Schneider, D. T.   +9 more
core   +1 more source

DataSheet_1_Expanding the molecular spectrum of tenosynovial giant cell tumors.docx

open access: yes, 2022
BackgroundWhile great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge.
Marie Karanian (8871731)   +12 more
core   +1 more source

Epidemiology of Knee Articular Cartilage Injuries in Patients Undergoing Arthroscopy: Insights From 25,293 Procedures at a High‐Volume Center

open access: yesOrthopaedic Surgery, Volume 18, Issue 4, Page 670-684, April 2026.
This large, single‐center study provides a comprehensive cross‐sectional overview of cartilage injuries among 25,293 patients who underwent primary knee arthroscopy between 2017 and 2023. We found an overall prevalence of 66.2%, with 26.6% classified as severe (Outerbridge Grade III–IV).
Yanfang Jiang   +6 more
wiley   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

open access: yesMedicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Home - About - Disclaimer - Privacy